Forge Biologics
Columbus, OH
6 partnership announcements in press monitoring
· Last scored 2026-09-07
61.2
Signal Score
○ FDA Inspections
✓ Clinical Trials (3)
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
Quick Facts: Forge Biologics
- Signal Score
- 61.2/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Columbus, OH
- Modalities
- AAV
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Forge Biologics
AAV specialist. Acquired by Ajinomoto.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
56.7
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
NCT05739643
Gene Transfer Clinical Trial for Infantile and Late Infantile...
PHASE1/PHASE2
Active Not Recruiting
Source: ClinicalTrials.gov · Retrieved Oct 06, 2026
Financial Stability
75.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
53.0
Capacity status: Expanding
Status
Recent Press20 articles
Clinical Activity 3 studies
NCT06308718
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in...
NA
Terminated
NCT05739643
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease...
PHASE1/PHASE2
Active Not Recruiting
NCT04693598
Gene Transfer Clinical Trial for Krabbe Disease
PHASE1/PHASE2
Active Not Recruiting
Source: ClinicalTrials.gov · Retrieved Oct 06, 2026
Recent News 20 articles
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - BioSpace
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership BioSpace
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and Manufacturing Pact - Contract Pharma
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and Manufacturing Pact Contract Pharma
Forge Biologics Highlights AAV Manufacturing Capabilities Ahead of ASGCT 2026 - TipRanks
Forge Biologics Highlights AAV Manufacturing Capabilities Ahead of ASGCT 2026 TipRanks
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - The Joplin Globe
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership The Joplin Globe
Forge Biologics Showcases AAV Manufacturing Capabilities Ahead of ASGCT 2026 - TipRanks
Forge Biologics Showcases AAV Manufacturing Capabilities Ahead of ASGCT 2026 TipRanks
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - Weekly Voice
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership Weekly Voice
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - PharmiWeb.com
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership PharmiWeb.com
Forge Biologics Showcases Gene Therapy Operations to Local STEM Students - TipRanks
Forge Biologics Showcases Gene Therapy Operations to Local STEM Students TipRanks
Forge Biologics Emphasizes European Gene Therapy Support and Regulatory Expertise - TipRanks
Forge Biologics Emphasizes European Gene Therapy Support and Regulatory Expertise TipRanks
Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites - BioSpace
Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites BioSpace
Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites - Business Wire
Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites Business Wire
Forge Biologics Highlights Manufacturing Challenges in Emerging Therapies - TipRanks
Forge Biologics Highlights Manufacturing Challenges in Emerging Therapies TipRanks
Forge Biologics Emphasizes Manufacturing Challenges in Emerging Therapies - TipRanks
Forge Biologics Emphasizes Manufacturing Challenges in Emerging Therapies TipRanks
Forge Biologics Targets Facilities Engineer to Support Manufacturing Infrastructure - TipRanks
Forge Biologics Targets Facilities Engineer to Support Manufacturing Infrastructure TipRanks
Forge Biologics Targets Facilities Engineering Hire to Support Manufacturing Infrastructure - TipRanks
Forge Biologics Targets Facilities Engineering Hire to Support Manufacturing Infrastructure TipRanks
Leadership Recognition Underscores Forge Biologics’ Gene Therapy Manufacturing Depth - TipRanks
Leadership Recognition Underscores Forge Biologics’ Gene Therapy Manufacturing Depth TipRanks
Forge Biologics Emphasizes Investor-Focused AAV Gene Therapy Manufacturing Strategy - TipRanks
Forge Biologics Emphasizes Investor-Focused AAV Gene Therapy Manufacturing Strategy TipRanks
Forge Biologics Recognition in CDMO Leadership Awards Signals Competitive Positioning - TipRanks
Forge Biologics Recognition in CDMO Leadership Awards Signals Competitive Positioning TipRanks
Forge Biologics Agrees to Develop and Manufacture Gene Therapy for Progeria - Genetic Engineering and Biotechnology News
Forge Biologics Agrees to Develop and Manufacture Gene Therapy for Progeria Genetic Engineering and Biotechnology News
Press Release Service: The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria - CRISPR Medicine News
Press Release Service: The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria CRISPR Medicine News
Frequently Asked Questions About Forge Biologics
How many clinical programs is Forge Biologics linked to?
Forge Biologics is associated with 3 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Forge Biologics's CDMO Signal Score?
Forge Biologics has a Signal Score of 61/100, based on quality, operations, financial stability, and capacity data.
Evaluating Forge Biologics for a manufacturing program?
Use the free AI matchmaker to compare Forge Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Cincinnati Children's Vector Production Facility
Cincinnati, OH
Signal Score: 75.2
AAV, Lentiviral
Andelyn Biosciences
Columbus, OH
Signal Score: 63.0
AAV, Lentiviral, Plasmid DNA
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars